C C Iwuji1,2, M Shahmanesh2,3, O Koole2,4, K Herbst2,5, D Pillay2,6, M J Siedner2,7, K Baisley2,4. 1. Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK. 2. Africa Health Research Institute, KwaZulu-Natal, South Africa. 3. Research Department of Infection & Population Health, University College London, London, UK. 4. London School of Hygiene and Tropical Medicine, London, UK. 5. SAPRIN, South African Medical Research Council, Cape Town, South Africa. 6. Division of Infection and Immunity, University College London, London, UK. 7. Harvard Medical School, Boston, MA, USA.
Abstract
INTRODUCTION: There is limited literature on the appropriateness of viral load (VL) monitoring and management of detectable VL in public health settings in rural South Africa. METHODS: We analysed data captured in the electronic patient register from HIV-positive patients ≥ 15 years old initiating antiretroviral therapy (ART) in 17 public sector clinics in rural KwaZulu-Natal, during 2010-2016. We estimated the completion rate for VL monitoring at 6, 12, and 24 months. We described the cascade of care for those with any VL measurement ≥ 1000 HIV-1 RNA copies/mL after ≥ 20 weeks on ART, including the following proportions: (1) repeat VL within 6 months; (2) re-suppressed; (3) switched to second-line regimen. RESULTS: There were 29 384 individuals who initiated ART during the period [69% female, median age 31 years (interquartile range 25-39)]. Of those in care at 6, 12, and 24 months, 40.7% (9861/24 199), 34% (7765/22 807), and 25.5% (4334/16 965) had a VL test at each recommended time-point, respectively. The VL results were documented at all recommended time-points for 12% (2730/22 807) and 6.2% (1054/16 965) of ART-treated patients for 12 and 24 months, respectively. Only 391 (18.3%) of 2135 individuals with VL ≥ 1000 copies/mL on first-line ART had a repeat VL documenting re-suppression or were appropriately changed to second-line with persistent failure. Completion of the treatment failure cascade occurred a median of 338 days after failure was detected. CONCLUSION: We found suboptimal VL monitoring and poor responses to virologic failure in public-sector ART clinics in rural South Arica. Implications include increased likelihood of morbidity and transmission of drug-resistant HIV.
INTRODUCTION: There is limited literature on the appropriateness of viral load (VL) monitoring and management of detectable VL in public health settings in rural South Africa. METHODS: We analysed data captured in the electronic patient register from HIV-positive patients ≥ 15 years old initiating antiretroviral therapy (ART) in 17 public sector clinics in rural KwaZulu-Natal, during 2010-2016. We estimated the completion rate for VL monitoring at 6, 12, and 24 months. We described the cascade of care for those with any VL measurement ≥ 1000 HIV-1 RNA copies/mL after ≥ 20 weeks on ART, including the following proportions: (1) repeat VL within 6 months; (2) re-suppressed; (3) switched to second-line regimen. RESULTS: There were 29 384 individuals who initiated ART during the period [69% female, median age 31 years (interquartile range 25-39)]. Of those in care at 6, 12, and 24 months, 40.7% (9861/24 199), 34% (7765/22 807), and 25.5% (4334/16 965) had a VL test at each recommended time-point, respectively. The VL results were documented at all recommended time-points for 12% (2730/22 807) and 6.2% (1054/16 965) of ART-treated patients for 12 and 24 months, respectively. Only 391 (18.3%) of 2135 individuals with VL ≥ 1000 copies/mL on first-line ART had a repeat VL documenting re-suppression or were appropriately changed to second-line with persistent failure. Completion of the treatment failure cascade occurred a median of 338 days after failure was detected. CONCLUSION: We found suboptimal VL monitoring and poor responses to virologic failure in public-sector ART clinics in rural South Arica. Implications include increased likelihood of morbidity and transmission of drug-resistant HIV.
Authors: Mark J Siedner; Mwebesa B Bwana; Mahomed-Yunus S Moosa; Michelle Paul; Selvan Pillay; Suzanne McCluskey; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi Journal: HIV Clin Trials Date: 2017-07-18
Authors: Niklaus Daniel Labhardt; Isaac Ringera; Thabo Ishmael Lejone; Molisana Cheleboi; Sarah Wagner; Josephine Muhairwe; Thomas Klimkait Journal: J Int AIDS Soc Date: 2017-07-19 Impact factor: 5.396
Authors: Sarah Swannet; Tom Decroo; Sheila M T L de Castro; Caroline Rose; Ruggero Giuliani; Lucas Molfino; Ana W Torrens; Walter S E D Macueia; Sharon Perry; Tony Reid Journal: Int Health Date: 2017-07-01 Impact factor: 2.473
Authors: Frank Tanser; Victoria Hosegood; Till Bärnighausen; Kobus Herbst; Makandwe Nyirenda; William Muhwava; Colin Newell; Johannes Viljoen; Tinofa Mutevedzi; Marie-Louise Newell Journal: Int J Epidemiol Date: 2007-11-12 Impact factor: 7.196
Authors: David Etoori; Iza Ciglenecki; Mpumelelo Ndlangamandla; Celeste G Edwards; Kiran Jobanputra; Munyaradzi Pasipamire; Gugu Maphalala; Chunfu Yang; Inoussa Zabsonre; Serge M Kabore; Javier Goiri; Roger Teck; Bernhard Kerschberger Journal: J Int AIDS Soc Date: 2018-10 Impact factor: 5.396
Authors: Jaysingh Brijkumar; Johnathan A Edwards; Brent A Johnson; Claudia Ordonez; Henry Sunpath; Mitch Lee; Mathew R Dudgeon; Lydia Rautman; Selvan Pillay; Pravi Moodley; Y V Sun; José Castillo-Mancilla; Jonathan Z Li; Daniel R Kuritzkes; Mohamed Y S Moosa; Vincent Charles Marconi Journal: HIV Med Date: 2022-01-12 Impact factor: 3.094
Authors: Zahra Reynolds; Suzanne M McCluskey; Mahomed Yunus S Moosa; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin L Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Pravi Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent A Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi; Mwebesa Bosco Bwana; Mark J Siedner Journal: HIV Med Date: 2021-11-09 Impact factor: 3.094
Authors: Mark J Siedner; Mahomed-Yunus S Moosa; Suzanne McCluskey; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Melendhran Pillay; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Rajesh T Gandhi; Brent A Johnson; Henry Sunpath; Mwebesa B Bwana; Vincent C Marconi Journal: Ann Intern Med Date: 2021-10-26 Impact factor: 51.598